Work

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma

Year: 2012

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-012-9819-5

Authors: Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P. de Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Robert Ilaria, M. L. Keohan

Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Instituto Alexander Fleming, Northwestern University, Instituto de Salud Carlos III, Hospital de Sant Pau, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, Moffitt Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Eli Lilly (United Kingdom), Eli Lilly (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W1986378982

FWCI: 1.03

Cites: 29

Cited by: 14

Related to: 10